HALEOS LABS growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−3.2%+1.9%
EBITDA−0.8%+15.8%
Net Income−5.0%+16.1%
EPS (adj.)−13.9%+14.7%
Total Assets+16.5%+4.8%
Total Equity+8.3%+6.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HALEOSLABS₹1,450.60

HALEOS LABS LIMITED

· Pharma & Health
₹ CrorePeersALBERTDAVDVALIANTLABMEDICOMEDICAMEQZIMLABAAREYDRUGSNECLIFEANUHPHRMcap ₹439 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-3.2+1.9
EBITDA-0.8+15.8
Net Income-5.0+16.1
EPS (adj.)-13.9+14.7
Total Assets+16.5+4.8
Total Equity+8.3+6.8
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.